Landmark NEI vision study supports important role of FloraGLO® Lutein and OPTISHARP® Zeaxanthin in reducing risk of progression to advanced AMD
The Association for Research in Vision and Ophthalmology (ARVO) has presented the results from AREDS2 at the Annual Meeting in Seattle, Wash., 5-9 May 2013. In summary, it reports that daily usage of eye health supplements containing 10 mg of FloraGLO® Lutein and 2 mg of OPTISHARP® Zeaxanthin as compared to a formula containing vitamins C, E beta-carotene and Zinc and Cupric Oxide (referred to as original AREDS formulation which gave a 25 – 30 percent reduction in AMD) did not reach additional significant reduction in risk to the original AREDS formulation of progression to advanced AMD, a leading cause of adult blindness. However, in a subgroup analysis comparing 10 mg FloraGLO Lutein and 2 mg of OPTISHARP Zeaxanthin with the groups given the original AREDS supplement, a statistically significant reduction in the progression to advanced AMD of 9 percent was seen for lutein and zeaxanthin in the entire study group. Details are published in the Journal of the American Medical Association.
A subgroup analysis in 1,055 eyes indicates that subjects with the lowest quintile of dietary intake of lutein and zeaxanthin (median 0.7 mg per day) but supplemented with 10 mg FloraGLO Lutein and 2 mg of OPTISHARP Zeaxanthin had a significant risk reduction of 26 % for progression to advanced AMD. These findings affirm the role of lutein and zeaxanthin as important contributors to risk reduction of AMD progression and the authors acknowledge the role of lutein and zeaxanthin in disease development and suggest further investigations. They also mention that the results of this study may not be generalizable to the wider US population, as the highly selected group studied was well nourished with a diet high in carotenoids and vegetables. In the US, dietary intake of lutein and zeaxanthin is typically less than 1 mg per day.
AREDS2 is a randomized trial conducted in more than 80 sites across the U.S. by the National Eye Institute (NEI) of the National Institutes of Health (NIH). This study follows AREDS1, which was published in 2001 and found that people at high risk of developing advanced stages of AMD lowered their risk by 25 – 30 percent when treated with a high-dose combination of vitamin C, vitamin E, beta-carotene, zinc and copper. AREDS2 assessed the effects of oral supplementation of certain eye nutrients in more than 4,000 participants ranging from 50-85 years of age, most of whom at the time of enrollment had intermediate AMD. It is the largest trial to date testing the effectiveness of lutein, zeaxanthin and omega-3 in adults with AMD. The AREDS2 study also found that circulating blood levels of lutein and zeaxanthin increased significantly in those receiving supplements, which may have a protective effect in eye disease.
The results of AREDS2, which provides evidence that participants supplemented with 10 mg of FloraGLO Lutein and 2 mg of OPTISHARP Zeaxanthin have a reduced risk of developing advanced AMD, also addressed the role of beta carotene as this was a part of the original AREDS formulation. A subgroup analysis of lutein and zeaxanthin and the original AREDS formulation without beta carotene as compared to the group lutein and zeaxanthin and the original AREDS formulation with beta carotene resulted in a significant risk reduction of 18 percent for progression to advanced AMD for the group receiving no beta carotene.
No beneficial or harmful effects of DHA + EPA for treatment of AMD could be demonstrated in this study. The authors comment on this finding that dose, duration of treatment and possibly the DHA:EPA ratio may have been inappropriate.
In summary, the effects observed in this study for its main study supplementation are consistent with other study reports on the beneficial roles of lutein and zeaxanthin in eye health. Finally it has to be noted that diseases such as AMD, with their long patho-etiological time-course and many genetic and environmental factors, are complex to study with an intervention of modest changes of nutrients.
“These results come at a critical time when our population is aging and eye health is a growing concern for many people around the globe,” said Jeff Flora, President, Kemin Human Nutrition and Health. “The number of people diagnosed with early AMD is projected to double by 2020 and a clinical research trial of this size confirms the importance of lutein and zeaxanthin supplementation to patients, supplement manufacturers and eye care professionals.”
“FloraGLO Lutein and OPTISHARP Zeaxanthin were shown to significantly reduce progression to advanced AMD when compared with no lutein or zeaxanthin,” said Will Black, Vice-President, Marketing, DSM Human Nutrition & Health. “This effect is amplified in participants with poor intake levels. Further research is required to clearly understand this beneficial effect, but it continues to be an area of great interest when you consider the typically low dietary intake of these nutrients in the US population.”
About FloraGLO, OPTISHARP, MEG-3® & Actilease®
Kemin’s FloraGLO Lutein and DSM’s OPTISHARP Zeaxanthin and MEG-3 Omega-3 are all formulated by DSM. FloraGLO Lutein and OPTISHARP Zeaxanthin are trusted sources of lutein and zeaxanthin because of their quality and established safety profile. Actilease technology maximizes nutrient absorption to achieve optimum bioavailability.
- Sourced from marigold flowers and purified from marigold flower oleoresin, FloraGLO Lutein is the world's leading patented, purified lutein, manufactured by Kemin and formulated by DSM.
- Identical to the zeaxanthin found in nature, OPTISHARP Zeaxanthin is produced using DSM’s superior formulation technology.
- Purified for safety and concentrated for potency, MEG-3 Omega-3 is naturally and sustainably sourced from clean, omega-3 rich ocean fish.
Kemin – Inspired Molecular Solutions™
Kemin (www.kemin.com) provides 'inspired molecular solutions' specifically developed to provide nutrition and health benefits for humans and animals. Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where approximately 500 specialty ingredients are made for the global feed and food industries as well as the health, nutrition and beauty markets. A privately held, family-owned and operated company, Kemin has more than 1,600 employees and operates in 90 countries with manufacturing facilities in Belgium, Brazil, China, India, Italy, Singapore, South Africa and the United States.
Kemin and DSM Strategic Alliance
In 2008, Kemin and DSM joined forces working under an exclusive strategic alliance. Kemin supplies FloraGLO brand lutein exclusively through DSM, and DSM globally commercializes FloraGLO brand lutein products through distributors and directly to customers. Customers and consumers benefit from the synergies achieved by the collaboration through DSM's global reach, unique formulation technology and broad product portfolio when combined with Kemin's lutein knowledge, intellectual property, technical know-how and market development expertise.
FloraGLO® is a registered trademark of Kemin Industries, Inc.
OPTISHARP® is a registered trademark of DSM
MEG-3® is a registered trademark of DSM
Actilease® is a registered trademark of DSM